Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 dec 2015 - 08:00
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug announces publication of initial PQ912 clinical data demonstrating inhibition of glutaminyl cyclase
Bericht
HALLE/SAALE, Germany, 15 December 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced that data from an extensive phase 1 study with PQ912, its lead glutaminyl cyclase (QC) inhibitor for the treatment of AD, have been published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, Volume 1, Issue 3, Pages 182-195. PQ912 is a first-in-class competitive inhibitor of glutaminyl cyclase, essential for the formation of pyroglutamate-Amyloid-beta (pGlu-Abeta). PGlu-Abeta seeds Abeta oligomers which, due to their hypertoxicity, are regarded as the key culprits behind AD.
Datum laatste update: 20 mei 2025